PRAX
NasdaqPRAXIS PRECISION MEDICINES, INC.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$0
2022
$2.4M
2023
$8.6M
2024
$0
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$0
Net Income—
Gross Profit—
Oper Income$-326.2M
EPS (dil)$-13.48
Rev/sh$0.00
FCF/sh$-8.94
Book/sh$31.50
Gross M—
Oper M—
Profit M—
FCF M—
ROE—
ROA—
ROIC-62.8%
R&D/Rev—
Rev Y/Y—
Rev 3Y CAGR—
EPS Y/Y-32.0%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+25.7%
Current Ratio10.22
Quick Ratio—
Debt/Eq—
Int Coverage—
Net Debt—
Total Debt—
Cash & Eq$357.7M
Total Assets$937.9M
Oper CF$-249.1M
Capex$56,000
Free CF$-249.1M
Buybacks—
Equity$878.1M
Liabilities$59.8M
Shs Outstand0.03B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 4 FY| USD | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $0 | $2.4M | $8.6M | $0 |
| Gross Profit | — | — | — | — |
| Operating Income | $-215.0M | $-126.4M | $-200.2M | $-326.2M |
| Net Income | $-214.0M | $-123.0M | $-183.0M | $-303.0M |
| Diluted EPS | $-69.65 | $-18.69 | $-10.21 | $-13.48 |
| Operating Cash Flow | $-185.0M | $-111.1M | $-131.8M | $-249.1M |
| Free Cash Flow | $-185.5M | $-111.2M | $-131.8M | $-249.1M |
COMMUNITY · $PRAX0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.